Hepatitis B

Dynavax Technologies has received funding from the National Institute of Allergy and Infectious diseases to study the differences between individuals who do and do not respond to vaccinations against the hepatitis B virus.

Hepatitis E

Health experts in China say they have developed an experimental vaccine that safely protects people against hepatitis E infection.

John Kerry

Sen. John Kerry (D – Mass.) introduced legislation on August 4 that would fund and direct the Department of Health and Human Services to create a national strategy to control viral hepatitis.

The surge in childhood vaccination coverage for hepatitis A that began in 2006 has since fallen off, the July 2 issue of the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report reveals.

Hepatitis B

According to the researchers at the Centers for Disease Control, rates of hepatitis B in children and young adults in the U.S. are down significantly.

Hepatitis A

Officials with the Pueblo City-County Health Department in Pueblo, Colorado, alerted the public to a possible hepatitis A exposure that may have occurred on May 31 at Desert Hawk at Pueblo West golf course.

Hepatitis

Officials with Dynavax Technologies recently announced the second of its planned safety assessments have been completed for Phase III trials of Heplisav, a vaccine designed to protect against hepatitis B., according to a tradingmarkets.com report.

Hepatitis B

Dynavax Technologies reports that it has completed immunizing over 2,000 subjects in a Phase 3 study of HEPLISAV, an adult hepatitis B vaccine.

NEW YORK — British drugmaker GlaxoSmithKline PLC said March 20 that it is launching a program in the United States to provide free vaccines to adults who don't have health insurance.

Dynavax Technologies Corp. said March 23 that the safety profile of its experimental hepatitis B vaccine Heplisav was comparable with GlaxoSmithKline’s hepatitis B vaccine Engerix-B, which recently got a regulatory approval.

World Health Organization

GENEVA — The World Health Organization said March 18 that it was suspending the use of the Indian-developed Shan5 combination vaccine, which is used against infections such as diphtheria, tetanus and hepatitis B.

Hepatitis B

Dynavax Technologies Corp. said March 16 that its auditors have expressed doubts about the company's ability to continue as a going concern as a result of the company's current financial position, according to Reuters.

Decades of vaccination and prevention efforts may have the hepatitis viruses on the run, according to a new report from the U.S. Centers for Disease Control and Prevention released March 10.

Hepatits B

About one in five babies born to mothers with hepatitis B aren't getting treatments that have been shown to prevent the infection in newborns, a study whose findings were released online March 8 in advance of the April print issue of Pediatrics.

Hepetitis B

AltraVax Inc. has acquired a vaccine development technology package that gives AltraVax an exclusive license to develop vaccines for infectious diseases and is targeting influenza, a treatment for hepatitis B and HIV.

Hepetitis B

BERKELEY, Calif. — Dynavax Technologies Corp. will start a 2,000-patient trial of its investigational adult hepatitis B vaccine, aiming for data in the first half of 2011, the San Francisco Business Times reported Feb. 8.

Hepatitis B

A Scottish life science firm has secured an additional $3.1 million in funding to develop new vaccines, BBC News reported.

Hepatitis B

NEW YORK — Our expanding waistlines may have outgrown doctors’ needles, researchers report in the March issue of Pediatrics.

Hepatitis B

Dynavax Technologies Corp. announced Jan. 12 the addition of two new senior executives to direct key commercial and clinical activities prior to the launch of Heplisav, an investigational adult hepatitis B vaccine.

Hepatitis B

WASHINGTON — Stepped-up vaccination requirements, a boost in resources for prevention and treatment, and a public awareness campaign are needed to curb the health threats posed by hepatitis B and hepatitis C.

World Health Organization

AMSTERDAM — Dutch biotech firm Crucell NV will likely look to add a sixth antigen to its portfolio of childhood vaccines as part of expected product add-ons after a stake sale to Johnson & Johnson, Reuters reported Dec. 15.

Hepatitis E

KAABONG, Uganda — An outbreak of Hepatitis E has killed 12 people out of 210 infected in Uganda’s northeastern region of Karamoja, The New Vision Web site reported, citing Michael Lochiyo, the health educator of Kaabong district in the region.

Hepatitis B

Dynavax Technologies Corp. announced Dec. 9 that its manufacturing facility in Dusseldorf, Germany, has been approved for the commercial production of hepatitis B surface antigen.

J. Joseph Kim

SAN DIEGO — Inovio Biomedical Corp. announced Nov. 30 that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio's electroporation technology.

HANOI, Vietnam — Through its commitment to immunization and other child health interventions, Vietnam has drastically reduced its child deaths, the GAVI Alliance announced Nov. 20 during its partner forum.

Pentavalent Vaccine

HANOI, Vietnam — Following the increasing impact of the GAVI Alliance on the vaccine market, the price of one of the major combination vaccines, the pentavalent, is falling considerably.

Fuad El-Hibri

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced that it has completed the acquisition of a 55,000-square-foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the city of Baltimore.

Dr. Michael Gale Jr.

SEATTLE— Kineta Inc. has announced that it has been awarded a $6.8 million subcontract from the National Institute of Allergy and Infectious Diseases to develop novel vaccine adjuvants (agents that help boost the immune system).

Fuad El-Hibri

GAITHERSBURG, Md. — Emergent BioSolutions announced that it acquired England-based Microscience Ltd., a privately held vaccine company primarily involved in the research and development of proprietary vaccines and immunotherapeutics.